TABLE 4.
Race and other demographic factors associated with neutropenia among paclitaxel patients
|
Grade 2 Neutropenia (N = 396) |
Grade 3 Neutropenia (N = 338) |
Grade 4 Neutropenia (N = 185) |
|||||
|---|---|---|---|---|---|---|---|
| N a | OR (95% CI) b | N | OR (95% CI) | N | OR (95% CI) | ||
| Race | |||||||
| White | 339 / 1733 | Reference | 278 / 1672 | Reference | 161 / 1555 | Reference | |
| Black | 49 / 179 | 1.47 (1.01–2.15) | 52 / 182 | 1.86 (1.27–2.72) | 19 / 149 | 1.16 (0.66–2.04) | |
| Other | 8 / 48 | 0.77 (0.35–1.72) | 8 / 48 | 0.90 (0.41–2.01) | 5 / 45 | 1.00 (0.36–2.80) | |
| Age | |||||||
| <55 | 125 / 617 | Reference | 111 / 603 | Reference | 48 / 540 | Reference | |
| 55 to <65 | 125 / 624 | 1.02 (0.75–1.38) | 92 / 591 | 0.81 (0.58–1.12) | 56 / 555 | 1.25 (0.79–1.99) | |
| 65 to <75 | 108 / 523 | 1.16 (0.84–1.60) | 90 / 505 | 1.03 (0.73–1.45) | 54 / 469 | 1.52 (0.95–2.43) | |
| ≥75 | 38 / 196 | 1.05 (0.68–1.64) | 45 / 203 | 1.30 (0.84–2.01) | 27 / 185 | 1.95 (1.09–3.50) | |
| Sex | |||||||
| Female | 240 / 1051 | Reference | 208 / 1019 | Reference | 118 / 929 | Reference | |
| Male | 156 / 909 | 0.83 (0.59–1.15) | 130 / 883 | 0.59 (0.42–0.82) | 67 / 820 | 0.71 (0.45–1.13) | |
| BMI | |||||||
| 18.5 to <25 | 134 / 612 | Reference | 108 / 586 | Reference | 59 / 537 | Reference | |
| <18.5 | 12 / 62 | 0.78 (0.36–1.70) | 14 / 64 | 1.23 (0.61–2.48) | 10 / 60 | 2.07 (0.89–4.82) | |
| 25 to <30 | 132 / 632 | 0.93 (0.70–1.25) | 99 / 599 | 0.91 (0.66–1.26) | 56 / 556 | 0.98 (0.64–1.50) | |
| 30 to <35 | 105 / 549 | 0.78 (0.57–1.06) | 97 / 541 | 0.91 (0.66–1.26) | 47 / 491 | 0.84 (0.53–1.32) | |
| ≥40 | 13 / 105 | 0.37 (0.19–0.71) | 20 / 112 | 0.65 (0.37–1.16) | 13 / 105 | 0.78 (0.38–1.60) | |
| Ever smoke | |||||||
| No | 186 / 857 | Reference | 167 / 838 | Reference | 85 / 756 | Reference | |
| Yes | 192 / 980 | 1.04 (0.80–1.36) | 159 / 947 | 0.89 (0.67–1.17) | 93 / 881 | 0.97 (0.67–1.41) | |
a
Reporting as counts of patients in category / sum of patients with no neutropenia and patients in category.
b
All variables included in the multinomial analysis with adjustments for mean treatment dose, number of treatment cycles, and base neutrophil count, prior platinum treatment, prior radiotherapy, and cancer site.